West Pharma (WST) Reports In-Line Q3 EPS; Narrows EPS Outlook

West Pharma (NYSE: WST) reported Q3 EPS of $0.53, in-line with the analyst estimate of $0.53. Revenue for the quarter came in at $376.7 million versus the consensus estimate of $371.25 million.

GUIDANCE:

West Pharma sees FY2016 EPS of $2.17-$2.22, versus prior guidance of $2.15-$2.25 and the consensus of $2.21. West Pharma sees FY2016 revenue of $1.51-1.52 billion, versus the consensus of $1.51 billion.

For earnings history and earnings-related data on West Pharma (WST) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Bristow Group to acquire Berry Aviation for $105 million
• UBS Reiterates Buy Rating on General Motors (GM) as Defense Opportunity in Focus